Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1128-1135

  Rothenberg, M L ^a   Eckardt, J R ^a   Kuhn, J G ^a   Burris III, H A ^a   Nelson, J ^a   Hilsenbeck, S G ^a   Rodriguez, G I ^a   Thurman, A M ^a   Smith, L S ^a   Eckhardt, S G ^a   Weiss, G R ^a   Elfring, G L ^a   Rinaldi, D A ^a   Schaaf, L J ^a   Von Hoff, D D ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTINEOPLASTIC ALKALOID; CAMPTOTHECIN DERIVATIVE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; INTERFERON; IRINOTECAN; LEVAMISOLE; LOPERAMIDE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLORECTAL CANCER; DIARRHEA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME;

EID: 0029966672     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1128     Document Type: Article

References (25)

1. Yokokura T, Sawada S, Nokata K, et al: Antileukemic activity of new camptothecin derivatives. Proceedings of the Japanese Cancer Association, 40th Annual Meeting, Sapporo, Japan, 1981, p 228
2. Yokokura T, Furuta T, Sawada S, et al: Antitumor activity of newly synthesized, lactone ring-closed and water-soluble camptothecin derivative in mice. Proceedings of the Japanese Cancer Association, 43rd Annual Meeting, Fukuoka, Japan, 1984, p 261
3. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
4. Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191, 1991
5. Shimada Y, Rothenberg ML, Hilsenbeck SG, et al: Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 5:202-206, 1994
6. Kawato Y, Furuta T, Aonuma M, et al: Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28:192-198, 1991
7. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
8. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
9. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992
10. Takeuchi S, Noda K, Yakushiji M, et al: Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 11:224, 1992 (abstr)
11. Takeuchi S, Dobashi K, Fujimoto S, et al: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn J Cancer Chemother 18:1681-1689, 1991
12. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991
13. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacokinetic study of the novel topoisomerase I inhibitor 7-ethyl- 10-[4-(1-piperidino)-1 -piperidino]carbonyloxycamptothecin (CPT-11) administered as a 90-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
14. de Forni M, Bugat R, Chabot GG, et al: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354, 1994
15. Abigerges D, Chabot GG, Armand J-P, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
16. Rothenberg ML, Kuhn JG, Burris HA, III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
17. Abigerges D, Armand JP, Chabot GG, et al: High dose intensity of CPT-11 administered as single dose every 3 weeks: The Institut Gustave Roussy experience. Proc Am Soc Clin Oncol 12:133, 1993 (abstr)
18. Abigerges D, Armand J-P, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994
19. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Physicians' Desk Reference: Compazine (prochlorperazine) (ed 49). Montvale, NJ, Medical Economics, 1995, p 2357-2359
21. Fleishman SB, Lavin MR, Sattler M, et al: Antiemetic-induced akathisia in cancer patients receiving chemotherapy. Am J Psychiatry 151:763-765, 1994
22. Marsoni S, Hoth D, Simon R, et al: Clinical drug development: An analysis of phase II trials, 1970-1985. Cancer Treat Rep 71:71-80, 1987
23. Bedikian AY, Stroehlein J, Korinek J, et al: A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colrectal cancer. Am J Clin Oncol 6:181-186, 1983
24. Haskell CM, Selch MT, Ramming KP: Colon and rectum, in Haskell CM (ed): Colon and Rectum in Cancer Treatment (ed 3). Philadelphia, PA, Saunders, 1990, pp 232-254
25. Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994